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Purpose: The chronic obstructive pulmonary disease (COPD) assessment test (CAT) is 
widely used to assess the impact of COPD symptoms on health status. Whilst the CAT 
consists of eight different items, details on the distribution of each item are limited. This 
study aimed to investigate the distribution and clinical implication of each CAT item, 
stratified by CAT severity group, in stable COPD patients.
Patients and Methods: This was a cross-sectional study at a single referral hospital in 
South Korea. Spirometry confirmed COPD patients with CAT measured at the first clinical 
visit were retrospectively identified. Patients were categorized into three groups: low (0 ≤ 
CAT < 10), medium (10 ≤ CAT < 20), and high (20 ≤ CAT ≤ 40) impact group. For the 
purpose of this analysis, the first four items (cough, sputum, chest tightness, and dyspnea) 
and the remaining four items (activities, confidence, sleep and energy) were also grouped as 
“pulmonary” and “extra-pulmonary”, respectively.
Results: A total of 815 patients were included, and mean (SD) forced expiratory volume in 1 
s (FEV1) was 62.8 (17.4) % pred. Among them, 300 patients (36.8%) were in the high impact 
group and had a greater exacerbation history and lower lung function. The proportion of 
“extra-pulmonary” items score was greater in patients with higher total CAT scores, with the 
activity and confidence items showing higher scores.
Conclusion: In our study, in addition to dyspnea, activity limitation is a particular problem 
in individual patients with higher CAT total scores, for which physicians need to pay more 
attention. Our study suggests that whilst CAT total score captures the overall impact of 
COPD, each item of the CAT contains potentially useful information in understanding the 
patient’s symptom burden.
Keywords: COPD, COPD assessment test, patient reported outcome, symptom
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by persistent respira-
tory symptoms and airflow limitation.1 Whilst chronic cough and sputum being the 
common symptoms,2,3 exertional dyspnea is the most characteristic symptom of COPD 
that often restricts exercise capacity and activities of daily life of patients.4–6 
Accordingly, patients with symptomatic COPD have reduced health-related quality of 
life, which leads to substantial socioeconomic burden.7 Thus, disease-specific health 
status questionnaires for comprehensive assessment of symptoms beyond dyspnea are 
recommended in COPD guidelines, including the St. George’s Respiratory 
Questionnaire (SGRQ)8 and the Chronic Respiratory Disease Questionnaire (CRQ).9 
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These tools are well validated and reliable but are too com-
plex to implement in clinical practice.
The COPD assessment test (CAT) is an easy and simple 
measurement with an eight-item questionnaire including 
severity of cough, sputum, chest tightness, dyspnea, activ-
ities, confidence, sleep, and energy.10–12 It is widely used in 
daily practice to assess and quantify the impacts of COPD 
symptoms on the health status, and correlates well with the 
SGRQ score in clinically stable COPD patients.12 It is one of 
the key determinants in assessing disease severity and guid-
ing treatment in Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) report.1 Furthermore, a significant 
increase in CAT total score at a clinic visit is useful to detect 
worsening or exacerbation of COPD.13,14
Previous studies on CAT mostly focused on total 
score,10–12 rather than each item of CAT. A few have inves-
tigated single CAT items with regard to COPD screening,15 
phenotypes,16,17 comorbidities,18,19 emphysema,18 and 
fatigue.2 However, studies on the distribution and clinical 
significance of single items in CAT based on CAT total 
scores are lacking. Therefore, we aimed to evaluate the 
distribution and clinical implication of each item of CAT 
according to the total CAT score of stable COPD patients.
Materials and Methods
Study Population
This is a cross-sectional study. Consecutive COPD patients 
were selected from the CLUE (COPD LUng Evolution) 
registry, an ongoing cohort at Samsung Medical Center (a 
1979-bed referral hospital in Seoul, South Korea) that 
consists of the patients who have post bronchodilator 
forced expiratory volume in 1 second (FEV1) over forced 
vital capacity (FVC) less than 0.7 with age over 40 years. 
Between January 2016 and April 2019, 875 COPD 
patients who were enrolled into the registry and measured 
CAT were retrospectively identified. We excluded 31 
patients who experienced acute exacerbation on the day 
of study visit, 17 patients who had a pulmonary resection 
or endobronchial valve insertion and 12 patients without 
matchable spirometry results. The final sample included 
815 patients (Figure 1). For this cross-sectional study, data 
of the first visit were used. The Institutional Review Board 
of Samsung Medical Center approved this study (No. 
2019–09-071-001) and the requirement for informed con-
sent was exempted as this study was a retrospective ana-
lysis of the de-identified data that was routinely collected 
during clinical practice.
COPD Assessment Test
The CAT consists of eight items including cough, sputum, 
chest tightness, dyspnea, activities, confidence, sleep and 
energy. Item scores range from 0 to 5 points resulting in 
a total CAT score ranging from 0 to 40 points.11 Based on 
CAT total scores, patients were categorized into three groups: 
low (0 ≤ CAT < 10), medium (10 ≤ CAT < 20), and high (20 ≤ 
CAT ≤ 40) impact group according to CAT users guide (http:// 
www.catestonline.org). In this study, the first four items 
(cough, sputum, chest tightness, and dyspnea) were grouped 
pragmatically, based on their content, into “pulmonary items” 
whilst the remaining four items (activities, confidence, sleep 
and energy) were grouped as “extra-pulmonary items”.20
Data Collection and Measurements
Data obtained from the CLUE cohort database included 
age, sex, smoking history, body mass index (BMI), mod-
ified medical research council (mMRC) dyspnea scale, 
COPD assessment test (CAT) score, history of acute 
exacerbation, and Charlson comorbidity index (CCI).21 
Acute exacerbation was defined as an outpatient clinic 
visit, hospitalization or an emergency room visit owing 
to one or more of the following: worsening of dyspnea, 
increased sputum volume and purulent sputum. In this 
study, we collected the history of moderate to severe 
exacerbation in the previous year, which was routinely 
recorded as the structured form during clinic visit.
Spirometry, diffusing capacity of the lung for carbon 
monoxide (DLco), and lung volumes were performed 
using a Vmax 22 system (SensorMedics, Yorba Linda, CA, 
USA) according to American Thoracic Society/European 
Respiratory Society criteria.22,23 Absolute values of FEV1 
and FVC were obtained and the percentages of predicted 
FEV1 and FVC were calculated using a reference from 
a representative Korean sample.24 Absolute DLco values 
(mL/mmHg/min) was obtained using the same apparatus 
and calculated into the percentage of predicted values 
using a formula based on a representative Korean 
sample.25 Moderate to severe decrease in DLco was defined 
as DLco ≤ 60% pred26 and hyperinflation was defined as 
residual volume (RV)/total lung capacity (TLC) > 40%.27
Validation Cohort
To validate the findings from the current study, data from 
a multicenter cohort of COPD patients were used. In brief, 
the Korean COPD Subgroup Study (KOCOSS) is an 
ongoing, multicenter observational cohort study, which has 
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recruited COPD patients from referral hospitals in South 
Korea since December 2011. Patients who were diagnosed 
with COPD by a pulmonologist, aged ≥ 40 years, had a post- 
bronchodilator FEV1/FVC < 0.7, and showed respiratory 
symptoms were included. For this study, we used the data 
of 2181 patients who were enrolled from January 2012 to 
December 2019. After excluding those who missed CAT (n 
= 19), a total of 2162 patients were analyzed.
Statistical Analysis
Although the CAT was developed to be unidimensional with 
no subdomains,11 for the purpose of this descriptive analysis, 
the items were grouped into two groups based on the face- 
validity of items that appear to be related. In addition, to 
provide a continuous estimate of increasing pattern of each 
CAT item according to the total CAT score, we used locally 
weighted scatterplot smoothing (Figure 2). We then analyzed 
the patients grouped by overall CAT impact score using the 
recommended banding (http://www.catestonline.org).
All data are presented as numbers (%) for categorical 
variables and means (standard deviation) for continuous 
variables. Categorical variables were compared using the 
Pearson chi-square test or Fisher’s exact test, whilst the 
Student’s t-test was used to compare continuous variables. 
To test for linear trends, the group category was included 
as a continuous variable in the regression models. All tests 
were two-sided, and p-values < 0.05 were considered sig-
nificant. All analyses were performed using Stata software 
(ver. 14.0; Stata Corporation, College Station, TX, USA).
Results
The baseline characteristics of 815 patients included in the 
analysis are summarized in Table 1. The mean age was 72.1 
(standard deviation 8.9) years and most patients were male 
(90.9%). According to the baseline CAT score, 182 (22.3%), 
333 (40.9%) and 300 (36.8%) patients were categorized as 
low, medium and high impact, respectively. The median age 
and male predominance were similar across the groups, 
Figure 1 Flowchart of study population.
Figure 2 Different increasing pattern of each CAT items according to total CAT score. (A) Pulmonary items (cough, sputum, chest tightness and dyspnea) and (B) Extra- 
pulmonary items (activities, confidence, sleep and energy).
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whereas prevalence of current smokers increased from less 
symptomatic to highly symptomatic group. The high impact 
group also had a lower BMI, more dyspnea and higher rate 
of previous exacerbations compared to the other groups. 
There was no significant trend in comorbidities across 
three groups. Table 2 shows the baseline pulmonary function 
of each group; post-bronchodilator FEV1, DLco, and RV/ 
TLC showed worsening trend with higher CAT score.
The proportional contribution of the four “pulmonary” 
items (cough, sputum, chest tightness and dyspnea) and 
four “extra-pulmonary” items (activities, confidence, sleep 
and energy) to the total CAT score are presented, split by 
impact severity group, in Figure 3. The proportion of 
extra-pulmonary item scores was progressively greater 
with higher overall CAT total score, whilst that of pul-
monary symptoms decreased accordingly.
Figure 4 further demonstrates the distribution of mean 
score for each CAT item. Dyspnea was the most predomi-
nant symptom overall, and the rest of the “pulmonary” items 
were proportionately higher with total CAT scores. In con-
trast, the “extra-pulmonary” items, particularly activities and 
confidence showed sharp increment between moderate 
impact group and high impact group. The absolute values 
of each CAT item are available in Supplementary Table E1. 
In addition, this pattern of deterioration of extra-pulmonary 
impacts was similar between patients with FEV1 < 50% pred 
(n = 179) and those with FEV1 ≥ 50% pred (n =636) 
(Supplementary Figure 1) and between patients with DLco 
Table 1 Baseline Characteristics of Patients According to Total CAT Score Groups
Total  
(N = 815)
CAT < 10  
(N = 182)
10 ≤ CAT < 20  
(N = 333)






Age, years 72.1 (8.9) 72.1 (8.9) 72.0 (9.0) 72.2 (8.8) 0.878 –
Sex, male 741 (90.9) 166 (91.2) 303 (91.0) 272 (90.7) 0.836 –
Smoking status <0.001 <0.001
Never 85 (10.4) 27 (14.8) 31 (9.3) 27 (9.0)
Former 544 (66.8) 128 (70.3) 228 (68.5) 188 (62.7)
Current 186 (22.8) 27 (14.8) 74 (22.2) 85 (28.3)
BMI (kg/m2)+ 23.5 (3.4) 24.0 (3.0) 23.2 (3.2) 22.8 (3.6) <0.001 <0.001
Underweight 54 (6.6) 8 (4.4) 17 (5.1) 29 (9.7)
Normal 300 (36.8) 51 (28.0) 114 (34.2) 135 (45.0)
Overweight 202 (24.8) 63 (34.6) 86 (25.8) 53 (17.7)
Obese 259 (31.8) 60 (33.0) 116 (34.8) 83 (27.7)
mMRC (n = 714)
≥ 2 328 (45.9) 36 (23.4) 102 (35.2) 190 (70.4) <0.001 <0.001
Any previous history of acute 
exacerbation (n = 710)‡
228 (32.1) 337 (23.1) 79 (28.2) 112 (41.5) <0.001 <0.001
Charlson comorbidity index 2.87 (1.95) 2.95 (1.82) 2.89 (1.99) 2.81 (1.95) 0.413 0.401
Treatment <0.001 <0.001
None 274 (33.6) 75 (41.2) 128 (38.4) 71 (23.7)
LAMA or LABA 119 (14.6) 31 (17.0) 60 (18.0) 28 (9.3)
LAMA/LABA 167 (20.5) 41 (22.5) 65 (19.5) 61 (20.3)
ICS/LABD# 107 (13.1) 22 (12.1) 35 (10.5) 50 (16.7)
ICS/LAMA/LABA 148 (18.2) 13 (7.1) 45 (13.5) 90 (30.0)
Notes: Data are mean (standard deviation) or number (%). *Adjusted for age and sex. +Categorized according to Asian-specific criteria into underweight (<18.5 kg/m2), 
normal weight (18.5 – <23 kg/m2), overweight (23 – <25 kg/m2), and obese (≥25 kg/m2). ‡ Moderate to severe exacerbation in the previous year. #Among 107 patients, 104 
patients were using ICS/LABA, 2 patients were using ICS and LAMA, and 1 patient were using ICS monotherapy. 
Abbreviations: CAT, COPD assessment test; BMI, Body mass index; mMRC, modified medical research council dyspnea scale; LAMA, Long-acting muscarinic antagonists; 
LABA, Long-acting beta agonists; ICS, Inhaled corticosteroid; LABD, Long-acting bronchodilators.
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≤ 60% pred (n =241) and those with DLco > 60% pred (n 
=350) (Supplementary Figures 2).
Discussion
In this study, we found that patients with high impact CAT 
scores (≥ 20) were more likely to be current smokers, have 
more dyspnea and previous exacerbation history and have 
lower lung function and BMI. In a further analysis on the 
distribution of each CAT item according to total CAT score 
categories, the proportion of “pulmonary” items score was 
much higher than that of “extra-pulmonary” items in 
patients with mild impact. However, the proportion of 
“extra-pulmonary” items score was markedly higher in 
the high impact group. We also found that CAT items 
about activities and confidence were most severely influ-
enced in the high impact group, and the pattern was 
similar in subgroups categorized by FEV1 50% pred or 
DLco 60% pred.
Beyond the total CAT score, we elaborated the distri-
bution and clinical significance of each component of 
CAT. Compared to patients with lower total CAT scores, 
in patients with high impact (CAT scores ≥ 20), the pro-
portional contribution of “pulmonary” items to the total 
score was less whilst the contribution of “extra- 
pulmonary” items increased up to 48.0%. When each of 
8 items was analyzed separately, the “pulmonary” item 
scores were proportionally higher across the impact 
groups, whilst “extra-pulmonary” items showed a bigger 
step increase with higher total CAT scores. This was seen 
particularly with the activities and confidence items. 
A similar observation was made during the development 
of the CAT showing that “confidence” better distinguished 
more severe patients.11 Our finding highlights that limita-
tion in physical activity plays a major role in impaired 
quality of life in high impact group. Whilst clinicians 
usually focus more on patients’ respiratory symptoms 
and pharmacological treatment during routine practice, 
our results suggest that CAT items can detect patients 
who suffer from deteriorated physical activities, particu-
larly before they become highly symptomatic in terms of 
total CAT scores. In this regard, clinicians should pay 
more attention to “extra-pulmonary” symptoms and seek 
individualized and comprehensive interventions, such as 
pulmonary rehabilitation.
Our findings are consistent with previous studies, 
which reported that CAT score correlates with diverse 
clinical features of COPD. Several studies have reported 
that the increased CAT score is associated with 
dyspnea28,29 and acute exacerbation state or its future 
risk.11–13,29–31 Whilst it is known that FEV1 has a weak 
correlation with CAT score,12,28 several studies have 
shown a correlation between total CAT scores and 
GOLD grades.12,29 In our study, we also found 
a correlation between total CAT scores and the degree of 
airflow limitation and DLco. However, it is of note that 
one third of patients with FEV1 < 50% pred had CAT score 
< 20, whereas one third of patients with FEV1 ≥ 50% pred 
had CAT score ≥ 20. As shown in the Supplementary 
Table 2 Baseline Pulmonary Function Parameters of Patients According to Total CAT Score Groups
Total  
(N = 815)
CAT < 10  
(N = 182)
10 ≤ CAT < 20  
(N = 333)
CAT ≥ 20  
(N = 300)
P value P for Trend
Post-bronchodilator spirometry
FVC, L 3.41 (0.85) 3.42 (0.84) 3.52 (0.77) 3.26 (0.92) <0.001 0.011
FVC, % pred 81.9 (16.5) 81.4 (14.6) 84.5 (15.4) 79.3 (18.2) <0.001 0.052
FEV1, L 1.83 (0.61) 1.99 (0.55) 1.93 (0.55) 1.62 (0.65) <0.001 <0.001
FEV1, % pred 62.8 (17.4) 68.0 (14.9) 66.0 (15.1) 55.9 (19.1) <0.001 <0.001
< 50% 179 (22.0) 20 (11.0) 46 (13.8) 187 (37.7) <0.001 <0.001
FEV1/FVC 53.5 (11.7) 58.4 (9.0) 54.8 (10.5) 49.1 (12.9) <0.001 <0.001
DLco, % pred (n = 591) 66.3 (21.0) 73.5 (17.9) 68.9 (20.5) 58.4 (21.0) <0.001 <0.001
≤ 60% 241 (40.8) 31 (24.2) 93 (36.1) 117 (57.1) <0.001 <0.001
Lung volume (n = 426)
RV/TLC 41.7 (9.7) 40.8 (9.1) 40.2 (9.0) 44.2 (10.5) <0.001 0.003
> 40% 213 (50.0) 43 (71.8) 88 (49.2) 82 (56.9) 0.060 0.018
Notes: Data are mean (standard deviation) or number (%). 
Abbreviations: CAT, COPD assessment test; FVC, Forced vital capacity; FEV1, Forced expiratory volume in 1s; RV, Residual volume; TLC, Total lung capacity; DLco, 
Diffusing capacity of the lung for carbon monoxide.
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Figure 1, patients had different degrees of airflow limita-
tion but showed visually similar distribution of each item 
of CAT when total CAT score was <20. This shows that 
FEV1 does not fully reflect the impact of COPD, empha-
sizing that FEV1 does not say it all.28
COPD is a systemic disease not only affecting the lungs 
but also having non-respiratory manifestations, including 
skeletal muscle dysfunction with atrophy and weakness, 
systemic inflammation and nutritional depletion.32,33 Our 
study showed the association between high CAT scores 
and a lower BMI, which is a surrogate marker of 
cachexia.34 GOLD also recommends that nutritional sup-
ports should be provided to malnourished COPD patients, 
which can improve overall quality of life.1,35 Similarly, the 
higher prevalence of smoking exposure among subjects 
with high CAT score might partly explain the effect of 
systemic inflammation on their extra-pulmonary manifesta-
tions. These findings suggest that patient reported outcomes 
Figure 3 Proportion contribution of four pulmonary items (cough, sputum, chest tightness and dyspnea) and four extra-pulmonary items (activities, confidence, sleep and 
energy) to the total CAT score, according to impact severity group. *Four patients had zero score in CAT.
Figure 4 Distribution of mean score for each CAT items according to impact severity group (absolute values are available in supplementary table E1).
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are essential component in understanding this complex dis-
ease and achieving the goal of reducing symptom burden 
and improving quality of life, by non-pharmacological and 
pharmacological therapies.
Our study had several limitations. First, this is 
a retrospective analysis of data from a single referral 
center, which limits its generalizability. To address this 
limitation, we performed the same analysis using the data 
of 2162 patients from the KOCOSS cohort. As shown in 
Figure 5 and Supplementary Table E1, the pattern of 
deterioration of CAT items was very similar in both 
cohorts (except for sleep). The clinical characteristics of 
KOCOSS patients were summarized in Supplementary 
Table E2. Second, our patient cohort showed a marked 
male predominance (> 90%) which has been consistently 
reported in multicenter studies from Korea that are based 
on pulmonology clinics.36,37 This is due to a selection 
bias, as the male predominance was lesser in national 
survey.38 In part, this is attributable to a very low female 
smoking rate (3.4%) in Korea.39 However, there was no 
gender difference in CAT scores in previous studies.12,40 
Third, due to the cross-sectional nature, we could not 
investigate the impact of each CAT items on clinical 
outcomes, such as future exacerbation or response to 
treatments. Further longitudinal studies with serially mea-
sured CAT are necessary to better understand the clinical 
utility of CAT in daily practice. Fourth, as we restricted 
the study population to stable COPD patients, we care-
fully reviewed and excluded patients who experienced 
acute exacerbation on the study visit (who were pre-
scribed systemic steroids or referred to emergency depart-
ment after clinic visit). However, co-existence of clinical 
instability caused by other disease could not be 
completely excluded. Lastly, although there was no sig-
nificant association between CCI and CAT total scores in 
our study, we lacked information on patients’ mental 
health. In the analysis using KOCOSS data 
(Supplementary Table E2), there were more patients 
with depressive disorder (defined as a Beck Depression 
Inventory ≥ 16 or more)41 in high impact group. It is 
known that depression and anxiety are associated with 
high CAT scores, especially with the extra-pulmonary 
items.19 Depression was also correlated with SGRQ 
score, particularly with impact and activity domain.42 
Thus, psychological problem may have contributed to 
the greater increase of extra-pulmonary items in high 
impact group, which should also be addressed as part of 
the integrated patient care.
Conclusion
Using the CAT total scores and distribution of individual 
items of CAT, we found that dyspnea is the most prominent 
symptom in all patient groups regardless of total impact 
categories. Whilst dyspnea increased proportionally with 
worsening impact of COPD, CAT items regarding activities 
and confidence showed a sharp deterioration when patients 
became highly impacted (CAT total score ≥ 20). This novel 
insight suggests a new look into CAT items such that clin-
icians need to pay more attention to patients’ activities 
beyond dyspnea and seek a comprehensive intervention.
Abbreviations
BMI, body mass index; CAT, COPD assessment test; CCI, 
Charlson comorbidity index; COPD, chronic obstructive 
pulmonary disease; CRQ, Chronic Respiratory Disease 
Questionnaire; DLco, diffusing capacity of carbon 
Figure 5 Distribution of mean score for each CAT items according to impact severity group in (A) CLUE registry (the present study, N = 815) and (B) KOCOSS cohort 
(multicenter cohort for validation, N = 2162).
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monoxide of the lung; FEV1, forced expiratory volume in 1 
s; FVC, forced vital capacity; GOLD, Global Initiative for 
Chronic Obstructive Lung Disease; mMRC, modified med-
ical research council; RV, residual volume; SGRQ, 
St. George’s Respiratory Questionnaire; TLC, total lung 
capacity.
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